Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) has announced that it will disclose its fourth quarter and full year fiscal 2022 financial results on October 31, 2022, prior to market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and key business topics including strategy, partnerships, and regulatory processes. Renalytix is a leader in kidney health, with its product KidneyIntelX™ receiving Breakthrough Designation from the FDA, aimed at improving kidney disease prognosis.

Positive

• KidneyIntelX™ granted Breakthrough Designation by FDA.
• Scheduled financial results may indicate positive financial performance.

Negative

• None.

NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial results on Monday, October 31, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link:  https://edge.media-server.com/mmc/p/y9qtsbmx

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth / Alice Woodings		Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
CapComm Partners
Peter DeNardo		Tel: 415-389-6400 or investors@renalytix.com

FAQ

When will Renalytix report its fourth quarter and full year fiscal 2022 financial results?

Renalytix will report its financial results on October 31, 2022.

What time is the Renalytix conference call scheduled?

The conference call is scheduled for 8:30 a.m. ET on October 31, 2022.

What is the significance of KidneyIntelX™ for Renalytix?

KidneyIntelX™ has received Breakthrough Designation from the FDA, indicating its potential for significant impact in kidney health management.

What topics will be discussed during the Renalytix conference call?

Key topics include financial results, business strategy, partnerships, and regulatory and reimbursement processes.